April 27th 2024
A mobile app may help to expedite treatment and identification for patients with GVHD.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Single-Tube Assay for CLL Optimizes Detection of Minimal Residual Disease
January 29th 2013A single tube 10-color assay for the detection of residual disease in chronic lymphocytic leukemia provides at least equivalent results to the international standardized flow cytometry approach to detection and requires fewer cells, uses fewer reagents, and allows for simpler analysis, according to a new study.
Inotuzumab Ozogamicin/Rituximab Combo for Lymphoma Yields High Response Rates, Long PFS
January 26th 2013The combination of two antibody-based targeting agents-inotuzumab ozogamicin and rituximab-demonstrated high response rates and long progression-free survival in patients with relapsed follicular lymphoma or relapsed diffuse large-B-cell lymphoma (DLBCL) in an international phase I/II multicenter, open-label study.
Study: Enzyme Plays Important Role in CML Stem Cell Reprogramming
January 19th 2013Researchers have identified an enzyme that plays an important role in the reprogramming of malignant progenitor cells in chronic myeloid leukemia. The enzyme, ADAR1, could represent a target for selecting and eradicating leukemia stem cells.
Richter's Syndrome: CLL Taking a Turn for the Worse
December 19th 2012Early results suggest that the new targeted therapies for CLL may have a profound impact on survival-and thus on the incidence of Richter's transformation. It will therefore become increasingly important to study Richter's transformation more assiduously, to diagnose it sooner, and to develop strategies to treat this extremely challenging entity.
Richter's Transformation in Chronic Lymphocytic Leukemia
December 19th 2012Richter's transformation, or Richter's syndrome, is an uncommon clinicopathological condition observed in about 5% to 10% of patients with chronic lymphocytic leukemia (CLL). This review summarizes advances in our understanding of the pathobiology and in the management of Richter's transformation in patients with CLL.
The Important Role of Secondary Treatment in Hodgkin Lymphoma
December 18th 2012It is time to move on to next key steps of improving recognition of treatment-resistant lymphoma at diagnosis, rather than at treatment failure, by optimally employing biomarkers and improving cure rates by integrating powerful but minimally toxic new systemic agents into primary treatment.
Treatment for Favorable Localized Hodgkin Lymphoma: the Final Answer Is Awaited
December 18th 2012The likelihood that combined-modality therapy will provide a small progression-free survival advantage is real but not likely to be equated to an overall survival advantage, as it depends on when one looks at the data. The studies to date demonstrate a late fall-off in survival due to one or another toxic effect of radiation.
ASH: Non-Chemo Regimen ‘Not Inferior’ in Newly Diagnosed APL
December 13th 2012A combination of all-trans retinoic acid (ATRA) and arsenic trioxide resulted in outcomes “at least not inferior” to those achieved when ATRA was used in combination with idarubicin chemotherapy in newly diagnosed patients with non–high-risk, acute promyelocytic leukemia.
ASH: Proteasome Inhibitor MLN9708 Shows Promise in Multiple Myeloma
December 12th 2012Preliminary findings presented at ASH suggest a “favorable emerging clinical profile” for once weekly administration of MLN9708 in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
ASH: Novel KSP Inhibitor Safe, Effective in Multiple Myeloma Phase II Trial
December 12th 2012ARRY-520, a novel selective kinesin spindle protein (KSP) inhibitor showed promising clinical activity both alone and combined with low-dose dexamethasone in a phase II clinical trial in patients with relapsed and refractory multiple myeloma.
ASH: Engineered T-Cell Therapy for Advanced Leukemia Achieves 2-Year Remission Rate
December 11th 2012Relapsed or refractory chronic lymphocytic leukemia and acute lymphoblastic leukemia patients have shown durable responses of almost 2 years to a novel T-cell engineering technique developed at the University of Pennsylvania Perelman School of Medicine in Philadelphia.
ASH: Updated PACE Findings Uphold Ponatinib Benefit in CML and Ph+ ALL
December 11th 2012Updated findings from the pivotal phase II PACE trial show sustained benefit of the investigational BCR-ABL tyrosine kinase inhibitor ponatinib in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
ASH: Early Results of Daratumumab in Multiple Myeloma Show Promise
December 10th 2012Data from an on-going early stage phase I/II trial of daratumumab in multiple myeloma continues to show promising activity. The dose-escalation study has shown that higher doses of daratumumab alone can reduce both bone marrow plasma cells as well as paraprotein.
ASH: Quizartinib Active in Subset of AML Patients
December 10th 2012Final results of a cohort from a phase II monotherapy trial of quizartinib in acute myeloid leukemia patients showed that more than half of patients 60 years of age and older who harbored an internal tandem duplication in the FMS-like tyrosine kinase 3 had a composite complete remission.
BELA: Bosutinib No Better Than Imatinib in Newly Diagnosed CML
November 19th 2012Despite a better major molecular response rate, the Src/Abl tyrosine kinase inhibitor bosutinib did no better than imatinib with regard to complete cytogenetic response in the BELA trial of patients with newly diagnosed chronic myeloid leukemia (CML).
CLL Therapy: The Increasing Importance of Predictive Markers
November 15th 2012It is easy to anticipate that as the complex biology of CLL continues to unfold, new prognostic and predictive biomarkers will be recognized. The discovery of genetic mutations that are key regulators of the development, growth, and proliferation of CLL leukemic cells augurs an alluring future.
Chronic Lymphocytic Leukemia With Deletion 17p: Emerging Treatment Options
November 15th 2012One strategy would be to consider “early treatment” for patients with deletion 17p, with the goal being to delay disease progression. This strategy is currently being explored in several prospective clinical trials employing treatment regimens such as FCR, lenalidomide (Revlimid), alemtuzumab (Campath), ofatumumab (Arzerra), and others.